Recruiting studies: Epidermal Growth Factor Receptor Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations
Phase 1 · 1 location(s) · National Cancer Center, China · NCT06362980 A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC
Phase 2 · 1 location(s) · Sichuan University · NCT06951464 Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT04322890 Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients
Phase 1/Phase 2 · 1 location(s) · China Medical University Hospital · NCT06071013 A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Ce
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07548060 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 2 · 35 location(s) · Apollomics Inc. · NCT03175224 Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT05503667 HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06824155 A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell
Phase 2 · 1 location(s) · Peking University Cancer Hospital & Institute · NCT05104788 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mut
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT04853342 Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2 · 26 location(s) · Sun Yat-sen University · NCT05334277 Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Phase 1 · 1 location(s) · Collin Blakely · NCT04085315 Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997 A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer
Phase N/A · 1 location(s) · Hunan Province Tumor Hospital · NCT05991193 Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced
Phase 3 · 166 location(s) · AstraZeneca · NCT06350097 Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.
NA · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT06238882 First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations i
Phase 1/Phase 2 · 94 location(s) · Bayer · NCT05099172 Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Phase 2 · 10 location(s) · Mark Vincent · NCT04335292 A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT07058519 A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR
Phase 2 · 80 location(s) · Taiho Oncology, Inc. · NCT05967689 Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor The
Phase 2 · 1 location(s) · Pusan National University Hospital · NCT07073365 Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Phase N/A · 146 location(s) · PrECOG, LLC. · NCT06538038 PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2 · 1 location(s) · Kristina A. Fanucci · NCT07222215 Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
NA · 2 location(s) · Henan Cancer Hospital · NCT06643000 A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doub
Phase 3 · 303 location(s) · AstraZeneca · NCT06417814 A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NA · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT06127979 A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal
Phase 3 · 1 location(s) · Allist Pharmaceuticals, Inc. · NCT06970639 A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI
Phase 3 · 211 location(s) · Relay Therapeutics, Inc. · NCT06982521 Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Phase 1 · 6 location(s) · Nuvectis Pharma, Inc. · NCT07315113

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.